ReviewStem cells translational medicine2021
Protecting islet functional viability using mesenchymal stromal cells.
Review in Stem cells translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Enhancing islet transplantation outcomes in T1DM: The promise of mesenchymal stem cells and exosomes.International journal of pharmaceutics: X · 2026Review
- Addressing bioenergetic deficits and restoring mitochondrial health in transplanted islets using mesenchymal stem cells.Stem cells translational medicine · 2026Article
- Islet response to photobiomodulation varies with the nature of the stress: insights from hypoxia-reperfusion.Lasers in medical science · 2026Article
- Apoptotic BMSCs reduce grafted islets apoptosis through the holo-Lcn2/Slc22a17/FeStem cell research & therapy · 2026Article
- Engineering Stem Cells for Islet Replacement Therapy: Recent Advances and Barriers for Clinical Translation.Cells · 2026Review
- β-Cell Mitochondrial Dysfunction: Underlying Mechanisms and Potential Therapeutic Strategies.Cells · 2025Review
- Preventing the onset of diabetes with precision delivery of mesenchymal stem cells to the pancreas in a preclinical model.Stem cell research & therapy · 2025Article
- A molecular systems architecture of the mesenchymal stromal cell microenvironment.Stem cells (Dayton, Ohio) · 2025Article
- Maturity-Onset Diabetes of the Young 10 (MODY10): A Comprehensive Review of Genetics, Clinical Features, and Therapeutic Advances.International journal of molecular sciences · 2025Review
- Article
- Amniotic Membrane and Mesenchymal Stem Cell Coalescence for Islet Transplantation in Experimental Diabetes in Rats.Journal of tissue engineering and regenerative medicine · 2025Article
- Alternative therapeutic strategies in diabetes management.World journal of diabetes · 2024Review
- Pancreatic islet transplantation: current advances and challenges.Frontiers in immunology · 2024Review
- Mesenchymal stromal cell secretory molecules improve the functional survival of human islets.Diabetic medicine : a journal of the British Diabetic Association · 2023Article
- A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome.Biomedicines · 2023Review
- IMT504 protects beta cells against apoptosis and maintains beta cell identity, without modifying proliferation.Physiological reports · 2023Article
- Islet transplantation-immunological challenges and current perspectives.World journal of transplantation · 2023Review
- Bone Marrow Mesenchymal Stem Cells-Derived miR-21-5p Protects Grafted Islets Against Apoptosis by Targeting PDCD4.Stem cells (Dayton, Ohio) · 2023Article
- Unlocking the post-transplant microenvironment for successful islet function and survival.Frontiers in endocrinology · 2023Review
- Research Progress on Mesenchymal Stem Cells for the Treatment of Diabetes and Its Complications.International journal of endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Islet transplantation is an emerging treatment for type 1 diabetes which offers the prospect of physiological control of blood glucose and reductions in acute hypoglycaemic episodes. However, current protocols are limited by a rapid decline in islet functional viability during the isolation process, culture period, and post-transplantation. Much of this can be attributed to the deleterious effects of hypoxic and cytokine stressors on β cells. One experimental strategy to improve the functional viability of islets is coculture or cotransplantation with mesenchymal stromal cells (MSCs). Numerous studies have shown that MSCs have the capacity to improve islet survival and insulin secretory function, and the mechanisms of these effects are becoming increasingly well understood. In this review, we will focus on recent studies demonstrating the capacity for MSCs to protect islets from hypoxia- and cytokine-induced stress. Islets exposed to acute hypoxia (1%-2% O
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.